

Alma Mater Studiorum Università di Bologna  
Archivio istituzionale della ricerca

Sardinian plants with antimicrobial potential. Biological screening with multivariate data treatment of thirty-six extracts

This is the final peer-reviewed author's accepted manuscript (postprint) of the following publication:

*Published Version:*

Mandrone M., Bonvicini F., Lianza M., Sanna C., Maxia A., Gentilomi G.A., et al. (2019). Sardinian plants with antimicrobial potential. Biological screening with multivariate data treatment of thirty-six extracts. *INDUSTRIAL CROPS AND PRODUCTS*, 137, 557-565 [10.1016/j.indcrop.2019.05.069].

*Availability:*

This version is available at: <https://hdl.handle.net/11585/689288> since: 2019-06-12

*Published:*

DOI: <http://doi.org/10.1016/j.indcrop.2019.05.069>

*Terms of use:*

Some rights reserved. The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

This item was downloaded from IRIS Università di Bologna (<https://cris.unibo.it/>).  
When citing, please refer to the published version.

(Article begins on next page)

1  
2  
3  
4  
5

6 This is the final peer-reviewed accepted manuscript of:

7 Mandrone M, Bonvicini F, Lianza M, Sanna C, Maxia A, Gentilomi GA, Poli F. Sardinian plants  
8 with antimicrobial potential. Biological screening with multivariate data treatment of thirty-  
9 six extracts. *Industrial Crops and Products*. 2019 Oct;137:57-565

10 The final published version is available online at: doi: 10.1016/j.indcrop.2019.05.069

11 Rights / License:

12 The terms and conditions for the reuse of this version of the manuscript are specified in the  
13 publishing policy. For all terms of use and more information see the publisher's website.

14

**Sardinian plants with antimicrobial potential. Biological screening with multivariate data  
treatment of thirty-six extracts**

Mandrone M.<sup>a</sup>, Bonvicini F.<sup>b,\*</sup>, Lianza, M.<sup>a</sup>, Sanna C.<sup>c</sup>, Maxia A.<sup>c</sup>, Gentilomi G.A.<sup>b,d</sup>, Poli F.<sup>a</sup>

<sup>a</sup>Department of Pharmacy and Biotechnology, University of Bologna, Via Irnerio 42, 40126  
Bologna, Italy

<sup>b</sup>Department of Pharmacy and Biotechnology, University of Bologna, Via Massarenti 9, 40138  
Bologna, Italy

<sup>c</sup>Department of Life and Environmental Sciences, University of Cagliari, Via Sant'Ignazio da  
Laconi 13, 09123, Cagliari, Italy

<sup>d</sup>Unit of Microbiology, S. Orsola-Malpighi Hospital-University of Bologna, Via Massarenti 9,  
40138 Bologna, Italy.

**\*Correspondence**

Dr. Francesca Bonvicini, Department of Pharmacy and Biotechnology, University of Bologna, Via  
Massarenti 9, 40138 Bologna, Italy  
E-mail: francesca.bonvicini4@unibo.it

## 40    **Abstract**

41    In this paper, thirty-six extracts from Sardinian plants were evaluated *in vitro* for their antimicrobial  
42    activity towards a panel of reference strains, *Staphylococcus aureus*, *S. epidermidis*, *Klebsiella*  
43    *pneumoniae* and *Escherichia coli*, and for their cytotoxicity on mammalian cells. The biological  
44    data, together with total phenolic and flavonoid content of the extracts, were treated by PCA  
45    (Principal Components Analysis), which highlighted the positive correlation among total phenolic  
46    content and increasing antibacterial activities, and a possible involvement of flavonoids in mitigate  
47    the cytotoxicity. Thirteen extracts displayed relevant IC<sub>50</sub> values (half maximal inhibitory  
48    concentration) on *S. aureus* (IC<sub>50</sub> from 1.4 to 153.6 µg/mL), ten out of them were active also  
49    against *S. epidermidis* (IC<sub>50</sub> from 3.9 to 150 µg/mL), seven against *K. pneumoniae* (IC<sub>50</sub> from 28.5  
50    to 97.5 µg/mL), and two against *E. coli* (IC<sub>50</sub> 74.9 and 156.3 µg/mL). In particular, three extracts  
51    obtained from *Pistacia terebinthus ssp. terebinthus*, *Cytinus hypocistis* and *Limonium morisianum*  
52    emerged as promising antibacterial candidates. They exhibited remarkable inhibitory activity  
53    towards bacterial strains from clinical specimens and presenting different antibiotic-resistance  
54    profiles.

55

56

## 57    **Keywords**

58    Antimicrobials; Sardinian plants; *Pistacia terebinthus ssp. terebinthus*; *Cytinus hypocistis*;  
59    *Limonium morisianum*; multivariate data treatment.

60

61

62

63

64

65

## 66 **1. Introduction**

67 In the current scenario, the clinical use of antibiotics, and therefore the effective treatment of  
68 bacterial infections, is under considerable threat due to the emergence of bacteria that have  
69 developed resistance to many classes of generally used antibiotics. Antibiotic-resistant bacterial  
70 infections are already widespread across the globe and very high rates of resistance have been ever-  
71 increasingly observed in common bacteria (WHO, 2014). Among *Staphylococcus* species, the  
72 prevalence of methicillin-resistant *S. aureus* and *S. epidermidis* (MRSA and MRSE, respectively)  
73 infections is growing worldwide and epidemiology is changing overtime. Although *S. aureus* and *S.*  
74 *epidermidis* are normal commensals of the skin and mucous membranes, MRSA is a leading cause  
75 of nosocomial infections and, more and more frequently, it is associated to community-acquired  
76 infections (mainly skin and wound infections) while MRSE has been identified as the most  
77 recurrent cause of health-care related bloodstream and device-related infections (Moellering, 2012;  
78 Rolo et al., 2012; May et al., 2014). Concerning Gram negative bacteria, high proportions of  
79 resistance to cephalosporins and fluoroquinolones have been reported for *Escherichia coli*, a normal  
80 inhabitants of the human intestinal microflora, and, of great concern, to carbapenems for *Klebsiella*  
81 *pneumoniae*, a primarily opportunistic bacterium that can be nosocomial or community acquired.  
82 These high reported resistances mean limitations to available treatment, which may be common in  
83 the population, such as urinary tract infections and pneumonia (Nordman et al., 2011).  
84 Generally, infections by drug-resistant bacteria have an increased risk of worse clinical outcome  
85 and death compared to infections by the respective susceptible strains, and treatments must rely on  
86 second-line drugs that are more expensive and, sometimes, they have severe side-effects for which  
87 monitoring is advisable, increasing costs even further.  
88 All these remarks have hastened and widened the quest for the discovery of novel agents for the  
89 treatment of bacterial infections.

90 In this context, plants represent a very important resource, producing hundreds of diverse  
91 metabolites, with medicinal and nutraceutical potential (Cragg & Newman 2013, Toledo et al.,  
92 2015; Chen et al., 2014; Fung et al. 2013). Among their bioactivities, plant metabolites were proved  
93 also endowed with antimicrobial potential (Coqueiro et al., 2016; Snene et al., 2017; Dikpinar et al.,  
94 2018; Mahadi et al., 2018). In addition to find new antimicrobial molecules, plant extracts resulted  
95 interesting to study also for their non-antimicrobial compounds, which might be essential for the  
96 total bioactivity of the extract, improving solubility, absorption and stability of the active  
97 metabolites. Moreover, some phytochemicals, despite not being antimicrobial by themselves,  
98 showed antibiotic adjuvant activity, due to the inhibition of pathogens resistance mechanisms  
99 (Abreu et al., 2016, Abreu et al., 2017).

100 Sardinia (Italy), due to its geographical isolation and high geological and geomorphological  
101 diversification, represents a hotspot for biodiversity within the Mediterranean basin (Médail &  
102 Quézel, 1997; Médail & Quézel, 1999; Marignani et al., 2017). This Island constitutes an extremely  
103 diverse and dynamic environment with wide range of habitats and high degree of endemism (Fois et  
104 al., 2017), driving plants to increase and diversify the production of their secondary metabolites in  
105 order to adapt, compete and communicate with other species (Jahangir et al., 2008; Wang et al.,  
106 2005). In fact, Sardinian plants were found generally endowed with peculiar features, both in  
107 respect of the phytochemical and genetic profiles (Bobo-Pinilla et al., 2016; Dettori et al., 2016;  
108 Marengo et al., 2017; Sanna et al., 2018a; Venditti et al., 2017; Venditti et al. 2018).

109 However, despite Sardinian endemic plants resulted interesting for their phytochemical and  
110 biological features, yielding also new molecular scaffolds (Cagno et al., 2017; Daino et al., 2018;  
111 Mandrone et al., 2015; Mandrone et al., 2017; Maxia et al., 2015; Ornano et al., 2016; Sanna et al.,  
112 2018b; Venditti et al., 2016), the majority of them remains still poorly investigated.

113 On this basis, thirty-six extracts obtained from Sardinian plants, including twelve endemic species,  
114 were evaluated *in vitro* for their antibacterial activity against Gram positive and Gram negative  
115 reference bacteria, and selected extracts were assayed on a panel of fifteen clinical isolates

116 presenting different antibiotic-resistance profiles. Moreover, cytotoxicity on mammalian epithelial  
117 cells was also tested.

118 The overall biological data, together with phenolic and flavonoid content, were summarized by  
119 principal component analysis (PCA).

## 120 2. Methods and materials

### 121 2.1. Plant material

122 Wild plants were harvested in Sardinia Island (Italy) during 2017 and 2018 and were identified by  
123 Dr. Cinzia Sanna and Prof. Andrea Maxia. Vouchers were deposited at the General Herbarium of  
124 the Department of Life and Environmental Sciences, University of Cagliari and reported in Table 1,  
125 where plants were listed in alphabetical order using the update nomenclature reported in the new  
126 checklist of Italian vascular flora (Bartolucci et al., 2018).

127

128 **Table 1** The table lists all the plants used in this study. The update botanical names, the plant organ  
129 used and their labels, families, places and dates of collection and voucher numbers were reported.

130

Plant name	Plant organ and sample label in brackets	Family	Location of harvesting	Harvesting date	Voucher
<i>Arbutus unedo</i> L.	Fruits (AuF)	Ericaceae	Jerzu	December 2017	Herbarium CAG 878
	Leaves (AuL)		Jerzu	December 2017	
<i>Asphodelus ramosus</i> L. subsp <i>ramosus</i>	Rhizome (ArRh)	Asphodelaceae	Geremeas	April 2017	Herbarium CAG 1405
	Leaves (ArL)		Geremeas	April 2017	
<i>Carlina gummifera</i> (L.) Less.	Leaves (CgL)	Asteraceae	Cala Surya (Cardedu)	July 2018	Herbarium CAG 770
<i>Centaurea calcitrapa</i> L.	Aerial parts (CcA)	Asteraceae	Siliqua	June 2017	Herbarium CAG 781
<i>Centaurea horrida</i> Badarò *	Aerial parts (ChA)	Asteraceae	Capo Falcone	June 2017	Herbarium CAG 777
<i>Centaurea napifolia</i> L.	Aerial parts (CnA)	Asteraceae	Uta	June 2017	Herbarium CAG 784

<i>Cistus monspeliensis</i> L.	Aerial parts (CmA)	Cistaceae	Cala Surya (Cardedu)	April 2018	Herbarium CAG 135
<i>Cistus salviifolius</i> L.	Aerial parts (CsA)	Cistaceae	Cala Surya (Cardedu)	April 2018	Herbarium CAG 135/C
<i>Cynara cardunculus</i> L.	Aerial parts (CycA)	Asteraceae	Siliqua	April 2017	Herbarium CAG 790
<i>Cytinus hypocistis</i> (L.) L.	Aerial parts (CyhA)	Cytinaceae	Gesturi	May 2017	Herbarium CAG 1200
<i>Ferula arrigonii</i> Bocchieri *	Leaves (FaL)	Apiaceae	Tharros	April 2017	Herbarium CAG 612/A
	Roots (FaR)		Tharros	April 2017	
<i>Galactites tomentosa</i> Moench	Aerial parts (GtA)	Asteraceae	Jerzu	September 2018	Herbarium CAG 789
<i>Genista corsica</i> (Loisel.) DC *	Aerial parts (GcA)	Fabaceae	Seui	May 2017	Herbarium CAG 286
<i>Glechoma sardoa</i> (Bég.) Bég. *	Aerial parts (GsA)	Lamiaceae	Gennargentu	June 2017	Herbarium CAG 1104
<i>Hypericum hircinum</i> L. ssp <i>hircinum</i> *	Aerial parts (HhA)	Hypericaceae	Jerzu	June 2018	Herbarium CAG 232
<i>Hypericum scruglii</i> Bacch., Brullo & Salmeri *	Aerial parts (HsA)	Hypericaceae	Jerzu	June 2018	Herbarium CAG 239/C
<i>Lavandula stoechas</i> L.	Aerial parts (LsA)	Lamiaceae	Cala Surya (Cardedu)	April 2017	Herbarium CAG 1067
<i>Limonium morisianum</i> Arrigoni *	Aerial parts (LmA)	Plumbaginaceae	Jerzu	December 2017	Herbarium CAG 909/G
<i>Myrtus communis</i> L.	Fruits (McF)	Myrtaceae	Cala Surya (Cardedu)	December 2018	Herbarium CAG 514
	Leaves (McL)		Poggio dei Pini	April 2018	
<i>Pistacia lentiscus</i> L.	Fruits (PIF)	Anacardiaceae	Cala Surya (Cardedu)	December 2017	Herbarium CAG 280
	Leaves (PIL)		Cala Surya (Cardedu)	December 2017	
<i>Pistacia terebinthus</i> L. ssp. <i>terebinthus</i>	Leaves (PtL)	Anacardiaceae	Jerzu	June 2018	Herbarium CAG 279
<i>Plagius flosculosus</i> (L.) Alavi & Heywood *	Aerial parts (PfA)	Asteraceae	Iglesias	July 2017	Herbarium CAG 743
<i>Ptilostemon casabonae</i> (L.) Greuter *	Aerial parts (PcA)	Asteraceae	Gairo Taqisara	June 2018	Herbarium CAG 796
<i>Rosmarinus officinalis</i> L.	Aerial parts (RoA)	Lamiaceae	Alghero	May 2017	Herbarium CAG 1091
<i>Santolina corsica</i> Jord. & Fourr *	Aerial parts (ScA)	Asteraceae	Monte Albo	November 2017	Herbarium CAG 732/A



<i>Scolymus hispanicus</i> L. <i>subsp. hispanicus</i>	Aerial parts (ShA)	Asteraceae	Sarroch	June 2018	Herbarium CAG 812
<i>Silybum marianum</i> (L.) Gaertn.	Aerial parts (SmA)	Asteraceae	Uta	May 2017	Herbarium CAG 801
<i>Smilax aspera</i> L.	Aerial parts (SaA)	Smilacaceae	Geremeas	May 2017	Herbarium CAG 1414
<i>Stachys glutinosa</i> L. *	Aerial parts (SgA)	Lamiaceae	Gennargentu	June 2017	Herbarium CAG 1099
<i>Tanacetum audibertii</i> (Req.) DC*	Aerial parts (TaA)	Asteraceae	Gennargentu	August 2018	Herbarium CAG 737/A
<i>Thymus herba barona</i> Loisel.	Aerial parts (ThA)	Lamiaceae	Gennargentu	June 2017	Herbarium CAG 1065

131 \*Endemic species of Sardinia

132

## 133 2.2. Chemicals and extracts preparation

134 All solvents and reagents were purchased from Sigma-Aldrich (Milan, Italy), MeOH was an  
135 analytical grade ( $\geq 99.9\%$ ).

136 Thirty mg of dried and powdered plant material were extracted by sonication for 30 minutes using  
137 1.5 mL of MeOH/H<sub>2</sub>O (1:1). Subsequently, samples were centrifuged ( $1700 \times g$ ) for 20 min, the  
138 supernatant was separated from the pellet and dried, firstly in vacuum concentrators (speedVac SPD  
139 101b 230, Savant, Italy) for two hours to remove MeOH, then the residual extracts were freeze-  
140 dried over night to completely remove the residual H<sub>2</sub>O finally yielding the crude extracts. For each  
141 sample different extracts were produced, in an adequate number to perform all the biological tests  
142 in replicates. This extraction procedure is designed to be performed relatively quickly and to  
143 prepare little quantity of extracts for *in vitro* bioactivity tests, been ideal for screenings of high  
144 number of plants. Moreover, this procedure allows a minimal waste of both solvents and plant  
145 material. The choice of a mid-polar solvent system such as aqueous MeOH and the use of  
146 sonication are recommended and used by several metabolomics studies (Kim & Verpoorte, 2010;  
147 Verpoorte, R. et al., 2007), where MeOH/H<sub>2</sub>O (1:1) turned out as the best choice for a first line  
148 extraction procedure for general plant material, since it allows to extract a broad spectrum of  
149 compounds. This protocol has been also used to compare biological activities of plants to their

150 phytochemical profile (Mandrone et al, 2018), resulting also suitable to facilitate further  
151 metabolomic studies to identify the active principles of the extracts.

152 For biological assays, stock solutions were prepared solubilizing extracts in water at 10 mg/mL,  
153 centrifuged to remove the pellet if present, and stored at 4°C until use.

### 154 *2.3. Total flavonoid and phenolic assays*

155 The assays were performed in Spectrophotometer Jasco V-530 as described by Chiocchio et al.  
156 (2018). Briefly, for total phenolic content analysis a calibration curve was constructed using 50 µL  
157 of different gallic acid stock solutions prepared in MeOH 80% (from 10 to 200 µg/mL) mixed with  
158 250 µL of Folin-Ciocalteu reagent (diluted 1:10) and 500 µL of H<sub>2</sub>O. Different stock solutions of  
159 extracts were prepared in water (from 0.05 to 0.2 mg/mL) and 50 µL of each stock were mixed with  
160 the same reagents as described above. Both calibration curve and samples were incubated at room  
161 temperature for 5 min before adding 800 µL of sodium carbonate solution (Na<sub>2</sub>CO<sub>3</sub> 20%). After 30  
162 min of incubation at 40°C, absorption was recorded at 760 nm. Total phenolic content was  
163 calculated by interpolation in the calibration curve and expressed as: mg GAE (gallic acid  
164 equivalent)/g of extract (dried weight).

165 Total flavonoid content was determined using rutin to perform the calibration curve. Different stock  
166 solutions of extracts were prepared in water (from 0.05 to 0.2 mg/mL) and 50 µL of each one were  
167 mixed with 450 µL of methanol and 500 µL of AlCl<sub>3</sub> (2% w/volume of methanol). The absorption  
168 at 430 nm was recorded after incubation (15 min) at room temperature. The calibration curve was  
169 obtained using 50 µL of different rutin stock solutions prepared in DMSO (from 1 to 100 µg/mL).  
170 Total flavonoid content of the extracts was calculated by interpolation in the calibration curve and  
171 expressed in terms of mg RE (rutin equivalent)/g of extract (dried weight). Analysis were  
172 performed in triplicate.

### 173 *2.4. Multivariate data analysis*

174 For multivariate analyses (PCA), data were subjected to UV (United Variance) scaling and the  
175 model was developed using SIMCA P+ software (v. 15.0, Umetrics, Sweden).

176 2.5. *Bacterial reference strains and clinical isolates*

177 *Staphylococcus aureus* ATCC 25293, *Staphylococcus epidermidis* (ATCC 12228), *Escherichia coli*  
178 (ATCC 25922) and *Klebsiella pneumoniae* (ATCC 9591) were obtained from the American Type  
179 Culture Collection. Subsequently, having defined the antibacterial properties of the extracts, the  
180 main active were assayed towards 15 clinical isolates recovered from different clinical specimens,  
181 and collected at the Microbiology Unit, St Orsola Malpighi University Hospital, Bologna, Italy.  
182 Strains included 5 *S. aureus* of which 3 methicillin-resistant (MRSA), 5 *S. epidermidis* of which 3  
183 methicillin-resistant (MRSE) and 5 *K. pneumoniae* of which 2 carbapenemase-producing (KPC-  
184 producing *K. pneumoniae*). Species identification and antimicrobial susceptibility testing were  
185 performed by Vitek2 semi-automated system (bioMerieux, France), and EUCAST criteria were  
186 used for the interpretation of results and for the definition of methicillin and carbapenem resistance.

187 2.6. *Determination of antibacterial activity*

188 The *in vitro* antibacterial activity of the thirty-six extracts was evaluated against four reference  
189 strains and some selected extracts towards clinical isolates by a broth microdilution method  
190 (Bonvicini et al., 2014; Bonvicini et al., 2017). The bacterial suspension, prepared in Mueller  
191 Hinton broth (Sigma-Aldrich, St. Louis, USA) was incubated with the extracts at 200 µg/mL or  
192 serially two-fold diluted from 200 µg/mL depending on the assay. A number of wells was reserved  
193 in each microplate for negative (no inoculum added) and positive growth controls. The microplate  
194 was incubated at 37°C for 24h, and subsequently the OD<sub>630 nm</sub> was spectrophotometrically measured  
195 (Multiskan Ascent microplate reader, Thermo Fisher Scientific Inc., Waltham, USA). Growth  
196 percentage values were determined as relative to the positive control. Extracts demonstrating an  
197 inhibitory activity superior to 70% at 200 µg/mL were defined as *active* and their IC<sub>50</sub> values  
198 corresponding to the sample concentrations giving rise to an inhibition of bacterial growth of 50%  
199 were obtained by the interpolation on the dose-response curves. Statistical analysis was carried out  
200 by nonlinear regression method using GraphPad Prism version 5.00 for Windows (GraphPad  
201 Software, San Diego California, USA). A one-way ANOVA was done for comparison between IC<sub>50</sub>

values obtained for the reference strains and clinical isolates followed by Dunnett's multiple comparison test to detect significant differences among groups.

## 2.7. Cell viability assay

African green monkey kidney cells (Vero ATCC CCL-81) were cultured in Eagle's Minimal Essential Medium (MEM) (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 10% fetal bovine serum (FBS) (Carlo Erba Reagents, Milan, Italy), 100 U/mL penicillin, and 100 µg/mL streptomycin at 37°C with 5 % CO<sub>2</sub>. For experiments, cells were seeded into 96-well plates at 10<sup>4</sup> cells/well, and incubated at 37°C for 24h. Cell density and incubation time were previously optimized (Bonvicini et al., 2018). Following washes with PBS (phosphate-buffered saline) to remove floating cells, monolayer was incubated with 100 µL of serially 2-fold dilution of the extract starting from 200 µg/mL, and with standard medium as positive control. The cell viability was assessed by a WST8-based assay according to the manufacturer's instructions (CCK-8, Cell Counting Kit-8, Dojindo Molecular Technologies, Rockville, MD, USA). After 48 h of incubation, culture medium was removed from each well, the monolayer was washed with PBS, and 100 µL of fresh medium containing 10 µL of CCK-8 solution were added and incubated for 2h at 37°C. Cell viability was measured at OD<sub>450/630 nm</sub> and expressed as the percentage of the cell viability relative to the untreated controls. The CC<sub>50</sub> values were obtained by the interpolation of percentage values on the dose-response curves.

## 3. Results and Discussion

### 3.1. Screening of biological activities and multivariate data analysis

The thirty-six extracts were assayed *in vitro* at 200 µg/mL to determine their antibacterial activity towards four reference strains and their cytotoxicity on mammalian epithelial cells. Overall data are reported in Tables S1 and S2 in Supplementary Material and Figure 1. Thirteen out of the thirty-six extracts resulted strong inhibitors of one or more bacteria (30% of bacterial growth compared to the extract-free control), as reported in Table 2. In particular, ten extracts inhibited the growth of both *S. aureus* and *S. epidermidis*, while three, PIF, RoA and SaA, showed activity only towards *S.*

228 *aureus*. Regarding the effectiveness on Gram negative bacteria, seven extracts were effective  
 229 against *K. pneumoniae*. Only two extracts, CyhA and PtL were able to reduce the growth of all  
 230 bacterial strains below the abovementioned threshold of activity (30%), reducing also *E. coli*  
 231 activity of 34% and 33%, respectively, which were the lowest values obtained out of the thirty-six  
 232 extracts tested.

233

234 **Table 2.** Bacterial growth of the reference strains treated with the 13 most active extracts at 200  
 235 µg/mL. Data are mean values and standard deviation obtained in two independent experiments  
 236 performed in triplicate. Percentage values are relative to the positive control (100% of growth).

237

Sample lable	<i>S. aureus</i> ATCC 25293	<i>S. epidermidis</i> ATCC 12228	<i>E. coli</i> ATCC 25292	<i>K. pneumoniae</i> ATCC 9591
AuL	16 ± 3	2 ± 3	58 ± 5	29 ± 5
CmA	8 ± 3	5 ± 5	66 ± 6	18 ± 4
CsA	11 ± 6	3 ± 4	47 ± 4	37 ± 10
CyhA	5 ± 4	3 ± 4	34 ± 14	19 ± 1
LmA	9. ± 4	10 ± 5	69 ± 12	44 ± 6
McF	19 ± 5	12 ± 7	69 ± 7	64 ± 6
McL	5 ± 8	4 ± 6	55 ± 8	26 ± 11
PIF	26 ± 9	49 ± 15	77 ± 8	42 ± 3
PIL	9 ± 8	7 ± 13	47 ± 5	24 ± 7
PtL	4 ± 5	3 ± 3	33 ± 6	17 ± 3
RoA	13 ± 6	74 ± 7	97 ± 6	89 ± 2
SaA	30 ± 11	111 ± 15	73 ± 13	76 ± 4
ThA	13 ± 3	21 ± 15	106 ± 10	90 ± 1

238

239 The screening pipeline on the thirty-six extracts included the evaluation of their effects on cell  
 240 viability and proliferation in order to discriminate between a specific ability to affect bacterial  
 241 growth or to a general toxic activity on mammalian cells. As depicted in Figure 1, among the thirty-  
 242 six extracts, eight strongly reduced mammalian cells metabolism below the 30% and, among these

243 extracts, six were labeled as *active* through the microbiological investigations, thus requiring further  
244 evaluations to specify their safety profile.

245

246 **INSERT FIGURE 1**

247

248 To gain comprehensive insights on the biological properties of all tested extracts, principal  
249 component analysis model (PCA) was build, using as set of x variables: the bioactivity data against  
250 the four bacterial strains (expressed as % of inhibition at 200 µg/mL), the cytotoxicity data  
251 (expressed as % of cell viability at 200 µg/mL), and total polyphenols and flavonoids content of the  
252 extracts, expressed as mg of gallic acid equivalents (GAE)/g of extract and % of rutin equivalents  
253 (RE)/g of extract, respectively. These latter phytochemical data are reported in Table S3 of  
254 Supplementary Material.

255 As shown by the PCA scatter plot (**Figure 2**), antibacterial activity (against all strains) and phenolic  
256 content followed a similar trend. In fact, extracts shifted on the positive side of the component t[1]  
257 (PC1) were generally endowed with high value of both antibacterial activity and phenolic content.  
258 Phenolic compounds might be involved in the positive effects observed, since they have been  
259 recognized as bioactive molecules with pronounced antimicrobial activity (Gomes et al., 2018;  
260 Scavo et al., 2019). Conversely, on the negative side of PC1 axis, the extracts showing no activity  
261 on bacteria and an extremely low content of phenolic and flavonoid compounds were grouped. On  
262 the positive side of the PC1 and along the negative side of the component t[2] (PC2) were placed  
263 the extracts with the highest cytotoxicity on mammalian cells, such as CycA and CcA, and showing  
264 only a medium activity against *Staphylococci* spp. High level of cytotoxicity on Vero cells was  
265 shown also by CyhA, AuL and CsA, which followed, in fact, a similar trend along the PC2, shifting  
266 toward the lower-right quadrant of the plot. Nevertheless, their strong antibacterial activities made  
267 those extracts still interesting for further investigations (IC<sub>50</sub> and SI determination), while CycA and

CcA were considered not interesting, due to their strong cytotoxicity while scant antibacterial activity.

On the upper part of the plot (positive PC2), the extracts with medium antibacterial activity while very low cytotoxicity were clustered. Interestingly, low toxicity on mammalian cells was associated to high flavonoids content, suggesting a possible cytoprotective role of these compounds, which are also renowned antioxidants (Hosseinzadeh & Nassiri-Asl, 2014). Among the samples endowed with high content of flavonoids, a peculiar case was represented by PtL, which, in fact, was identified as an outlier in the PCA model. This extract showed high content of both phenols and flavonoids, high antibacterial activity against all strains tested and very low cytotoxicity.

The herein described model, providing a graphical overview of all biological data, facilitates also considerations on extracts obtained from plants belonging to the same genus. In particular, samples included three different species of *Centaurea* genus (*C. calcitrapa*, *C. napifolia* and *C. horrida*), and two different species of *Pistacia* (*P. lentiscus* and *P. terebinthus ssp. terebinthus*), *Cistus* (*C. salvifolius* and *C. monspeliensis*) and *Hypericum* (*H. scruglii* and *H. hircinum ssp. hircinum*).

Regarding the three *Centaurea* species (CcA, CnA and ChA), they yielded very similar results, namely they were proved not active against all pathogens tested and were also poor in phenols and flavonoids. However, while CnA and ChA were also not cytotoxic on Vero cells, CcA was one of the highly cytotoxic extract of the dataset. Regarding the two *Cistus* species, CsA and CmA, they were placed very close in the PCA plot, since they showed a similar trend in both bioactivities and phenolic/flavonoids content. The same behavior was observed for the two species of *Hypericum* (HsA and HhA), which resulted both rich in flavonoids, not cytotoxic, while endowed with moderate antibacterial activity. Finally, the two *Pistacia*, PIL and PtL, were both strongly active against bacterial strains, even though PtL was more enriched in flavonoids and less cytotoxic than PIL.

INSERT FIGURE 2

294

295 As shown in **Figure 3**, the majority of the samples studied were plant leaves or aerial parts, one was  
296 constituted by rhizomes (ArRh), one by roots (FaR), and three of them were fruits (PIF, McF and  
297 AuF). In case of *Myrtus communis* and *Pistacia lentiscus*, both fruits and leaves extracts were tested  
298 and proved to be active and characterized by similar features, appearing very close into the PCA  
299 scatter plot. Conversely, only leaves of *Arbutus unedo* (AuL) were active, while fruits (AuF), being  
300 not active, were placed on the opposite quadrant of the plot.

301

302 **INSERT FIGURE 3**

303

### 304 3.2. Antibacterial activity and selectivity

305 The active subset of the thirteen extracts was further assayed *in vitro* towards some selected  
306 bacterial strains to obtain IC<sub>50</sub> values on the specific dose-response curves. Based on data in Table  
307 3, some general remarks can be drawn. Of the thirteen extracts inhibiting *S. aureus*, five displayed  
308 potent one-digit µg/mL IC<sub>50</sub> values and CyhA resulted the most effective *S. aureus* inhibitor (IC<sub>50</sub> =  
309 1.4 µg/mL); of the ten extracts active towards *S. epidermidis* four exhibited comparable inhibitory  
310 effectiveness, and LmA displayed the highest activity (IC<sub>50</sub> = 3.9 µg/mL). Concerning Gram  
311 negative bacteria, according to generally lower inhibition rates, IC<sub>50</sub> values for the active extracts  
312 were superior compared to those obtained for Gram positive strains, however worthy of note for  
313 raw plant extracts (Cos et al., 2006). The extracts of CyhA and McL resulted the most potent  
314 against *K. pneumoniae* (IC<sub>50</sub> = 28.5 µg/mL and IC<sub>50</sub> = 37.0 µg/mL, respectively) and the first one,  
315 being active even towards *E. coli* (IC<sub>50</sub> = 74.9 µg/mL), displayed a broad spectrum antibacterial  
316 activity. Differences in susceptibility between Gram positive and Gram negative bacteria are strictly  
317 related to the presence of the outer membrane and the lipopolysaccharides in the latter cells; these  
318 structures form an additional barrier that account for the Gram negative increased permeability  
319 threshold to many molecules.



320

321 **Table 3.** Antibacterial activity of the thirteen selected extracts expressed as IC<sub>50</sub> (µg/mL of extract),  
 322 defined as the concentration giving rise to an inhibition of growth of 50% compared to the drug-free  
 323 control. Data are reported as mean values and 95% confidence interval.

324

Sample lable	<i>S. aureus</i> ATCC 25293	<i>S. epidermidis</i> ATCC 12228	<i>E. coli</i> ATCC 25292	<i>K. pneumoniae</i> ATCC 9591
AuL	31.9 [26.2-38.8]	10.1 [9.3-10.9]	n.d. <sup>§</sup>	93.8 [81.8-107.6]
CmA	5.3 [4.4-6.5]	12.4 [11.1-13.9]	n.d.	64.65 [57.0-73.2]
CsA	9.0 [7.9-10.4]	29.5 [26.4-32.9]	n.d.	97.5 [80.6-118.1]
CyhA	1.4 [0.9-1.9]	8.0 [7.5-8.5]	74.9 [57.9-96.9]	28.5 [22.8-35.6]
LmA	9.2 [6.8-12.3]	3.9 [2.5-6.1]	n.d.	n.d.
McF	15.4 [10.7-21.9]	8.8 [7.5-10.5]	n.d.	n.d.
McL	7.5 [6.0-9.3]	9.7 [8.9-10.9]	n.d.	37.0 [28.3-48.4]
PIF	144.5 [126.0-165.6]	n.d.	n.d.	n.d.
PIL	27.3 [21.6-34.5]	56.8 [48.1-67.2]	n.d.	48.0 [40.6-56.7]
PtL	62.9[48.6-81.4]	103.1 [92.6-109.0]	156.3[138.1-177.0]	49.0 [42.8-56.0]
RoA	99.2 [83.1-118.5]	n.d.	n.d.	n.d.
SaA	153.6 [129.1-182.7]	n.d.	n.d.	n.d.
ThA	63.3 [55.5-72.1]	150.0 [131.0-171.8]	n.d.	n.d.

325 <sup>§</sup> n.d. = not determined

326

327 Dose-effect experiments on Vero cells were finally carried out to establish their safety on non-  
 328 malignant epithelial cells. Table 4 reports the CC<sub>50</sub> values and the corresponding selectivity index  
 329 (SI), calculated as CC<sub>50</sub>/IC<sub>50</sub> ratio, for the bacterial strain more susceptible to inhibition. Samples  
 330 obtained from CyhA, LmA and McL presented very high SI in relation to Vero cells on  
 331 *Staphylococci* spp. and only moderate values were obtained on *K. pneumoniae*, thus suggesting a  
 332 preferential inhibitory activity towards bacterial cells with respect to eukaryotic cells.

333

**Table 4.** Cytotoxicity of active extracts against Vero cells and Selectivity Indexes (SI). CC<sub>50</sub> is defined as the concentration giving rise to an inhibition of cell metabolism of 50% compared to the drug-free control. Data are reported as mean values and 95% confidence interval. SI = selective index corresponding to the ratio between CC<sub>50</sub> and IC<sub>50</sub>.

Sample lable	CC <sub>50</sub> (µg/mL)	SI
AuL	41.7 [35.0-49.7]	4.1 ( <i>S. epidermidis</i> )
CmA	88.2 [69.6-111.7]	16.5 ( <i>S. aureus</i> )
CsA	53.7 [43.5-66.3]	5.9 ( <i>S. aureus</i> )
CyhA	90.3 [75.2-108.3]	64.7 ( <i>S. aureus</i> ); 3.2 ( <i>K. pneumoniae</i> )
LmA	>200	>51.0 ( <i>S. epidermidis</i> )
McF	>200	>22.6 ( <i>S. epidermidis</i> )
McL	120.2 [92.9-155.6]	16.1 ( <i>S. aureus</i> ); 3.3 ( <i>K. pneumoniae</i> )
PIF	>200	>1.4 ( <i>S. aureus</i> )
PIL	84.2 [74.2-95.5]	3.1 ( <i>S. aureus</i> )
PtL	>200	4.1 ( <i>K. pneumoniae</i> )
RoA	>200	>2.0 ( <i>S. aureus</i> )
SaA	>200	>1.3 ( <i>S. aureus</i> )
ThA	>200	>3.2 ( <i>S. aureus</i> )

### 3.3. Clinical isolates

The three extracts selectively inhibiting bacterial growth were assayed also towards a broad array of relevant multi-resistant pathogens recovered from biological specimens. In particular, CyhA, LmA and PtL were assayed against *S. aureus*, *S. epidermidis* and *K. pneumoniae* strains, respectively. Data are reported in Table 5. Remarkably, the extracts proved to be active towards all the isolates and no statistically significant differences (ANOVA followed by Dunnett's Multiple comparison) were highlighted comparing IC<sub>50</sub> values of isolates, regardless their antibiotic resistance profile (see Tables S4, S5 and S6 in the Supplementary Material), and reference strains. This is clinically relevant considering that isolates may present phenotypic and genetic heterogeneity compared to laboratory reference strains thus some differences in susceptibility may occur.

350  
351  
352  
353

**Table 5.** IC<sub>50</sub> values of the three selected extracts towards clinical isolates. Data are reported as mean values and 95% confidence interval.

CyhA Vs <i>S. aureus</i>	IC <sub>50</sub> (µg/mL)	Antibiotic-resistance profile
ATCC 25293	1.4 [0.9-1.9]	
MSSA 1	1.6 [1.3-1.9]	CM <sup>S</sup> , E <sup>S</sup> , GMN <sup>S</sup> , LVX <sup>S</sup> , OX <sup>S</sup> , P <sup>R</sup> , TE <sup>S</sup> , SXT <sup>S</sup>
MSSA 2	2.8 [2.1-3.9]	CM <sup>R</sup> , E <sup>R</sup> , GMN <sup>S</sup> , LVX <sup>S</sup> , OX <sup>S</sup> , P <sup>S</sup> , TE <sup>S</sup> , SXT <sup>S</sup>
MRSA 1 <sup>§</sup>	2.6 [1.9-3.6]	GMN <sup>S</sup> , LVX <sup>R</sup> , OX <sup>R</sup> , P <sup>R</sup> , TE <sup>S</sup> , TEC <sup>S</sup> , SXT <sup>S</sup> , VA <sup>S</sup>
MRSA 2 <sup>§</sup>	3.2 [2.4-4.4]	GMN <sup>S</sup> , LVX <sup>R</sup> , OX <sup>R</sup> , P <sup>R</sup> , TE <sup>S</sup> , TEC <sup>S</sup> , SXT <sup>S</sup> , VA <sup>S</sup>
MRSA 3 <sup>§</sup>	1.9 [1.6-2.2]	CM <sup>R</sup> , E <sup>R</sup> , GMN <sup>S</sup> , LVX <sup>R</sup> , OX <sup>R</sup> , P <sup>R</sup> , TEC <sup>S</sup> , TE <sup>S</sup> , SXT <sup>S</sup> , VA <sup>S</sup>
<b>LmA Vs <i>S. epidermidis</i></b>		
ATCC 12228	3.9 [2.5-6.1]	
MSSE 1	2.6 [1.0-6.7]	CM <sup>S</sup> , E <sup>R</sup> , GMN <sup>S</sup> , LVX <sup>S</sup> , OX <sup>S</sup> , TE <sup>S</sup> , SXT <sup>S</sup>
MSSE 2	4.2 [2.1-8.3]	CM <sup>S</sup> , E <sup>S</sup> , GMN <sup>S</sup> , LVX <sup>S</sup> , OX <sup>S</sup> , P <sup>R</sup> , TE <sup>S</sup> , SXT <sup>S</sup>
MRSE 1 <sup>§</sup>	3.0 [2.1-8.4]	CM <sup>S</sup> , E <sup>R</sup> , GMN <sup>S</sup> , LVX <sup>S</sup> , OX <sup>R</sup> , P <sup>R</sup> , TE <sup>S</sup> , TEC <sup>S</sup> , SXT <sup>R</sup>
MRSE 2 <sup>§</sup>	6.7 [3.9-11.5]	CM <sup>S</sup> , E <sup>S</sup> , GMN <sup>S</sup> , LVX <sup>S</sup> , OX <sup>R</sup> , TE <sup>S</sup> , SXT <sup>R</sup> , VA <sup>S</sup> , TEC <sup>S</sup>
MRSE 3 <sup>§</sup>	3.7 [1.8-7.8]	CM <sup>S</sup> , DA <sup>S</sup> , E <sup>I</sup> , GMN <sup>S</sup> , LVX <sup>R</sup> , OX <sup>R</sup> , TE <sup>S</sup> , SXT <sup>S</sup> , VA <sup>S</sup> , TEC <sup>S</sup>
<b>PtL Vs <i>K. pneumoniae</i></b>		
ATCC 9591	49.0 [42.8-56.0]	
<i>Kp 1</i>	48.7 [42.0-56.5]	AK <sup>S</sup> , AMC <sup>R</sup> , CTX <sup>R</sup> , CFZ <sup>R</sup> , CIP <sup>R</sup> , FOS <sup>S</sup> , GMN <sup>S</sup> , TZP <sup>S</sup> , SXT <sup>R</sup>
<i>Kp 2</i>	46.1 [37.5-56.6]	AK <sup>S</sup> , AMC <sup>S</sup> , CTX <sup>S</sup> , CFZ <sup>S</sup> , CIP <sup>S</sup> , FOS <sup>S</sup> , GMN <sup>S</sup> , TZP <sup>S</sup> , SXT <sup>S</sup>
<i>Kp 3</i>	45.5 [34.7-59.7]	AK <sup>S</sup> , AMC <sup>S</sup> , CTX <sup>S</sup> , CFZ <sup>S</sup> , CIP <sup>S</sup> , FOS <sup>R</sup> , GMN <sup>S</sup> , TZP <sup>S</sup> , SXT <sup>S</sup>
<i>KPC-Kp 1*</i>	53.0 [42.2-66.5]	AK <sup>R</sup> , AMC <sup>R</sup> , AMP <sup>R</sup> , CFZ <sup>R</sup> , CIP <sup>R</sup> , EPM <sup>R</sup> , GMN <sup>S</sup> , MEM <sup>R</sup> , TZP <sup>R</sup> , SXT <sup>R</sup> , TGC <sup>I</sup> , CS <sup>S</sup>
<i>KPC-Kp 2*</i>	47.3 [44.0-56.9]	AK <sup>S</sup> , AMC <sup>R</sup> , AMP <sup>R</sup> , CFZ <sup>R</sup> , CIP <sup>R</sup> , EPM <sup>R</sup> , GMN <sup>R</sup> , MEM <sup>I</sup> , TZP <sup>R</sup> , SXT <sup>R</sup> , TGC <sup>S</sup> , CS <sup>S</sup>

354  
355  
356  
357  
358  
359  
360  
361  
362  
363

AK = Amikacin; AMC = Amoxicillin/Clavulanic Acid; AMP = Ampicillin; CM = Clindamicyn; CTX = Cefotaxime; CFZ = Ceftazidime; CIP = Ciprofloxacin; CS = Colistin; EPM = Ertapenem; E = Erythromycin; FOS = Fosfomycin; GMN = Gentamicin; LVX = Levofloxacin; MEM = Meropenem; OX = Oxacillin; P = Penicillin; SXT = Trimethoprim/Sulfamethoxazole; TE = Tetracycline; TEC = Teicoplanin; TZP = Piperacillin/Tazobactam, TGC = Tigecycline; VA = Vancomycin

R = Resistant; S = Susceptible; I = Intermediate, as defined following the EUCAST guidelines

<sup>§</sup>*Staphylococcus* species resistant to oxacillin were declared, by convention, methicillin-resistant.

\*Carbapenemase-producing *K. pneumoniae*.

364

365 *3.3 Traditional uses, bioactivities and phytochemical data of the three selected plants.*

366 The effectiveness of these selected extracts validates the Sardinian plants *Cytinus hypocistis*,  
367 *Pistacia terebinthus ssp. terebinthus* and *Limonium morisianum* as important source of  
368 antimicrobial compounds. These plants might be interesting for the development of food  
369 supplements and herbal products with antibacterial activity. Moreover, since *Limonium morisianum*  
370 is an endemic plant of Sardinia, the obtained results might contribute also to valorize the  
371 biodiversity of the territory and the development of local industries.

372 *Cytinus hypocistis* is a parasitic plant belonging to Cytinaceae family that grows on roots of *Cistus*  
373 *spp.* It has been used in Sardinian traditional medicine as astringent, tonic and haemostatic (Loi et  
374 al., 2002), to soften corns and hard skin, and to soothe epidermal inflammations (Ballero et al.,  
375 1997). Despite this wealth of traditional uses, its chemical composition is largely unknown.  
376 Hydrolysable tannins were previously identified as the main components (Magiatis et al., 2001),  
377 confirming the high phenolic content of CyhA extract observed in this study, and among them,  
378 isoterchebin, belonging to the ellagitannin class, was characterized (Schildknecht et al., 1985).

379 Given the well-known antimicrobial properties of hydrolysable tannins (Buzzini et al., 2008) it is  
380 likely that these compounds might be responsible for the observed antibacterial activity of CyhA.  
381 Recently, Zucca et al. (2015) found antimicrobial activity of *C. hypocistis* but using an extraction  
382 procedure different from the one performed in this work. Chiocchio et al. (2018) reported also the  
383 anti-elastase and anti-tyrosinase activities of this plant. Moreover, antimalarial and antitumor  
384 properties of this plant have also been described (Fokialakis et al., 2007; Magiatis et al., 2001).

385 *Pistacia terebinthus ssp. terebinthus* (Anacardiaceae), commonly known as terebinth or turpentine  
386 tree, is a small deciduous tree widely distributed in the Middle East and Southern Europe. In  
387 Sardinia, it grows only on a calcareous restricted area of east coast (Usai et al. 2006). The  
388 consumption of *P. terebinthus ssp. terebinthus* in the Mediterranean countries traced back to ancient  
389 times. For instance, leaves of this plant have been used for the treatment of burns and the branch

390 resin for bronchitis and other respiratory afflictions, as well as for anti-inflammatory and antipyretic  
391 properties (Topcu et al., 2007). The mature fruits were used as a diuretic and for urinary  
392 inflammations, stomachache (Cakilcioglu et al., 2010), stomach ulcers (Polat et al., 2013),  
393 antiseptic, hypotensive and for headache (Agelet and Vallès 2003). The resin is used as a chewing  
394 gum and as food additive (Schoina et al., 2015). In Sardinia the decoction has been used to treat  
395 catarrhal cough (Bruni et al., 1997), while the resin as expectorant, diaphoretic, analgesic, tonic and  
396 to obtain an ointment used for the treatment of bladders (Atzei 2003). *P. terebinthus* ssp.  
397 *terebinthus* has been reported to be rich in essential oil, proteins, organic acids, sugars, flavonoids,  
398 tannins and resinous substances (Couladis et al., 2003; Marengo et al., 2018; Ozcan, 2004; Ozcan et  
399 al., 2009; Piras et al., 2017; Pulaj et al., 2016; Usai et al., 2006). Several studies highlighted  
400 remarkable differences in the essential oil composition of this plant, attributable to geographic and  
401 climatic features (Couladis et al., 2003; Dhifi et al., 2013; Duru et al., 2003; Ismail et al., 2013;  
402 Marengo et al., 2018; Piras et al., 2017; Ulukanli et al., 2014; Pulaj et al., 2016). *P. terebinthus* ssp.  
403 *terebinthus* is reported to be active as: antibacterial, antifungal, antioxidant, cytotoxic,  
404 neuroprotective, antiinflammatory and insecticidal agent (Dhifi et al., 2013; Duru et al., 2003; Orhan  
405 et al., 2012; Ismail et al., 2013; Kavak et al., 2010; Kordali et al., 2003; Piras et al., 2017; Ulukanli  
406 et al., 2014; Pulaj et al., 2016; Topcu et al., 2007).

407 *Limonium morisianum* (Plumbaginaceae) is a dwarf frutex endemic and exclusive of calcareous  
408 mountains of Sardinia. To the best of our knowledge, no information on its use in Sardinian  
409 traditional medicine is available, since it is a very rare species. *Limonium* spp. are reported to  
410 contain several classes of active components, such as hydrolysable and condensed tannins,  
411 alkaloids, flavonoids, sterols, terpenes, saponins, coumarins, and amino acids (Blainski et al. 2013;  
412 Medini et al. 2014; Gadetskaya et al. 2015; Medini et al. 2015; de Oliveira Caleare et al. 2017).  
413 Moreover, myricetin, myricetin 3-*O*-rutinoside, myricetin-3-*O*-(6"-galloyl)- $\beta$ -D-galactopyranoside,  
414 (-)-epigallocatechin 3-*O*-gallate, tryptamine, ferulic and phloretic acids have been identified from  
415 its aerial parts (Sanna et al., 2018). Definitely, *L. morisianum* has been slightly studied both

416 phytochemically and biologically. Recently, the antiviral activity has been reported against HIV-1  
417 and Ebola viruses (Sanna et al., 2018c; Daino et al., 2018), as well as the ability to inhibit tyrosinase  
418 and elastase enzymes (Chiocchio et al., 2018). No information on antimicrobial and cytotoxic  
419 activities has been previously reported for any extract of this plant.

#### 420 **4. Conclusions**

421 This work reports the antimicrobial activity of some plants growing spontaneously in Sardinia  
422 (Italy). Thirty-six extracts were assayed *in vitro* towards four reference bacterial strains and  
423 evaluated for their cytotoxicity on mammalian epithelial cells.

424 The results of the biological screening, together with total phenolic and flavonoid content of the  
425 extracts, were processed through Principal Component Analysis (PCA), which highlighted the  
426 positive correlation among total phenolic content and increasing antibacterial activities, and a  
427 possible involvement of flavonoids in mitigate the cytotoxicity against eukaryotic cells.

428 A significant activity was observed for thirteen extracts at non-cytotoxic concentration, and among  
429 them three emerged for their selective and potent inhibitory effect on bacterial growth; *Cytinus*  
430 *hypocistis* proved to be a broad spectrum antibacterial extract, mainly active towards *S. aureus* (IC<sub>50</sub>  
431 1.4 µg/mL), *Limonium morisianum* exhibited a potent anti-staphylococcal properties and *Pistacia*  
432 *terebinthus ssp. terebinthus* resulted the extracts with the highest SI on *K. pneumoniae*. These  
433 extracts, when tested towards isolates obtained from biological specimens and with different  
434 antibiotic-resistance profiles, confirmed their effectiveness to inhibit bacterial growth, thus  
435 validating their potential as antimicrobial agents.

#### 436 **Funding**

437 This work was supported by Fondazione Cassa di Risparmio di Imola, which contributed to the  
438 scholarship of one of the authors (M.L.).

#### 439 **Declarations of interest**

440 None

#### 441 **References**

442 Abreu AC, Paulet D, Coqueiro A, Malheiro J, Borges A, Saavedra MJ, Choi YH, Simões M., 2016.  
 443 Antibiotic adjuvants from *Buxus sempervirens* to promote effective treatment of drug-resistant  
 444 *Staphylococcus aureus* biofilms. RSC Advances 6, 95000-95009.  
 445 <https://doi.org/10.1039/C6RA21137B>.

446 Abreu AC, Coqueiro A, Sultan AR, Lemmens N, Kim HK, Verpoorte R, Wamel WJ, Simões M,  
 447 Choi YH., 2017. Looking to nature for a new concept in antimicrobial treatments: Isoflavonoids  
 448 from *Cytisus striatus* as antibiotic adjuvants against MRSA. Scientific Reports. 7(1), 3777.  
 449 <https://doi.org/10.1038/s41598-017-03716-7>.

450 Agelet A, Vallès J., 2003. Studies on pharmaceutical ethnobotany in the region of Pallars (Pyrenees,  
 451 Catalonia, Iberian Peninsula). Part II. New or very rare uses of previously known medicinal plants.  
 452 J Ethnopharmacol. 84(2–3), 211–227. [https://doi.org/10.1016/S0378-8741\(02\)00319-7](https://doi.org/10.1016/S0378-8741(02)00319-7).

453 Atzei A.D., 2003. Le piante nella tradizione popolare della Sardegna. Carlo Delfino editore, Sassari,  
 454 Italia.

455 Ballero M, Sacchetti, G, Poli F., 1997. Plants in folk medicine in the territory of Perdasdefogu  
 456 (Central Sardinia, Italy). Allonia 35,157-164.

457 Bartolucci F., Peruzzi L., Galasso G., Albano A., Alessandrini A., Ardenghi N.M.G., Astuti G.,  
 458 Bacchetta G., Ballelli S., Banfi E., Barberis G., Bernardo L., Bouvet D., Bovio M., Cecchi L., Di  
 459 Pietro R., Domina G., Fascetti S., Fenu G., Festi F., Foggi B., Gallo L., Gottschlich G., Gubellini  
 460 L., Iamónico D., Iberite M., Jiménez-Mejías P., Lattanzi E., Marchetti D., Martinetto E., Masin  
 461 R.R., Medagli P., Passalacqua N.G., Peccenini S., Pennesi R., Pierini B., Poldini L., Prosser F.,  
 462 Raimondo F.M., Roma-Marzio F., Rosati L., Santangelo A., Scoppola A., Scortegagna S., Selvaggi  
 463 A., Selvi F., Soldano A., Stinca A., Wagensommer R.P., Wilhalm T. & Conti F., 2018. An updated  
 464 checklist of the vascular flora native to Italy. Plant Biosystems - An International Journal Dealing

465 with all Aspects of Plant Biology, 152 (2), 179-303.  
 466 <https://doi.org/10.1080/11263504.2017.1419996>.

467 Bobo-Pinilla J., Barrios de León S.B., Seguí Colomar J., Fenu G., Bacchetta G., Peñas de Giles J.,  
 468 Martínez-Ortega M.M., 2016. Phylogeography of *Arenaria balearica* L. (Caryophyllaceae):  
 469 evolutionary history of a disjunct endemic from the Western Mediterranean continental islands.  
 470 PeerJ, 4: e2618. <https://doi.org/10.7717/peerj.2618>.

471 Bonvicini F., Mandrone M., Antognoni F., Poli F., Gentilomi G.A., 2014. Ethanolic extracts of  
 472 *Tinospora cordifolia* and *Alstonia scholaris* show antimicrobial activity towards clinical isolates of  
 473 methicillin-resistant and carbapenemase-producing bacteria. Natural Product Research, 28(18),  
 474 1438-1445. <https://doi.org/10.1080/14786419.2014.909421>.

475 Bonvicini F., Antognoni F., Mandrone M., Protti M., Mercolini L., Lianza M., Gentilomi G. A., Poli  
 476 F., 2017. Phytochemical analysis and antibacterial activity towards methicillin-resistant  
 477 *Staphylococcus aureus* of leaf extracts from *Argania spinosa* (L.) Skeels. Plant Biosyst. 151 (4),  
 478 649-656. <https://doi.org/10.1080/11263504.2016.1190418>.

479 Bonvicini F., Lianza M., Mandrone M., Poli F., Gentilomi G.A., Antognoni F., 2018. *Hemidesmus*  
 480 *indicus* (L.) R. Br. extract inhibits the early step of herpes simplex type 1 and type 2 replication.  
 481 New Microbiologica, 41(3), 187-194.

482 Blainski A, Lopes GC, De Mello JCP., 2013. Application and analysis of the folin ciocalteu method  
 483 for the determination of the total phenolic content from *Limonium brasiliense* L. Molecules. 18,  
 484 6852–6865. <https://doi.org/10.3390/molecules18066852>.

485 Bruni A, Ballero M, Poli F., 1997. Quantitative ethnopharmacological study of the Campidano  
 486 Valley and Urzulei district, Sardinia, Italy. J. Ethnopharmacol 57, 97-124.  
 487 [https://doi.org/10.1016/S0378-8741\(97\)00055-X](https://doi.org/10.1016/S0378-8741(97)00055-X).



488 Buzzini P, Arapitsas P, Goretti M, Turchetti B, Pinelli P, Ieri F, Romani A., 2008. Antimicrobial  
 489 and antiviral activity of hydrolysable tannins. *Mini-Rev Med Chem.* 8(12), 1179–1187.  
 490 <https://doi.org/10.2174/138955708786140990>.

491 Cagno V., Sgorbini B., Sanna C., Cagliero C., Ballero M., Donalisio M., Bicchi C., Lembo D.,  
 492 Rubiolo P., 2017. In vitro anti-herpes simplex virus-2 activity of *Salvia desoleana* Atzei & V. Picci  
 493 essential oil. *PLoS ONE*, 12(2), e0172322. <https://doi.org/10.1371/journal.pone.0172322>.

494 Cakilcioglu U, Turkoglu I., 2010. An ethnobotanical survey of medicinal plants in Sivrice (Elazığ-  
 495 Turkey). *J. Ethnopharmacol.* 132(1), 165–175. <https://doi.org/10.1016/j.jep.2010.08.017>.

496 Chen P., Li C., Li X., Li J., Chu R., Wang H., 2014. Higher dietary folate intake reduces the breast  
 497 cancer risk: a systematic review and meta-analysis. *Br. J. Cancer.* 110, 2327-2338.  
 498 <https://doi.org/10.1038/bjc.2014.155>.

499 Chiocchio I., Mandrone M., Sanna C., Maxia A., Tacchini M., Poli F., 2018. Screening of a  
 500 hundred plant extracts as tyrosinase and elastase inhibitors, two enzymatic targets of cosmetic  
 501 interest. *Ind. Crops. Prod.* 122, 498-505. <https://doi.org/10.1016/j.indcrop.2018.06.029>.

502 Coqueiro, A., Choi, Y. H., Verpoorte, R., Gupta, K. B., De Mieri, M., Hamburger, M., Bolzani, V.  
 503 D.S., 2016. Antistaphylococcal prenylated acylphoroglucinol and xanthenes from *Kielmeyera*  
 504 *variabilis*. *J. Nat. Prod.* 79, 470-476. <https://doi.org/10.1021/acs.jnatprod.5b00858>.

505 Cos P., Vlietinck A.J., Berghe D.V., Maes L., 2006. Anti-infective potential of natural products:  
 506 How to develop a stronger in vitro ‘proof-of-concept’. *J. Ethnopharmacol.* 106, 290-302.  
 507 <https://doi.org/10.1016/j.jep.2006.04.003>.

508 Couladis M., Özcan M., Tzakou O., Akgu A., 2003. Comparative essential oil composition of  
 509 various parts of the turpentine tree (*Pistacia terebinthus* L) growing wild in Turkey. *Sci. Food*  
 510 *Agric.* 83,136–138. <https://doi.org/10.1002/jsfa.1295>.

511 Cragg, G. M, Newman, D.J., 2013. Natural products: a continuing source of novel drug leads.  
 512 Biochim. Biophys. Acta.1830(6), 3670–3695. <https://doi.org/10.1016/j.bbagen.2013.02.008>.

513 Daino G.L., Frau A., Sanna C., Rigano D., Distinto S., Madau V., Esposito F., Fanunza E., Bianco  
 514 G., Taglialatela Scafati O., Zinzula L., Maccioni E., Corona A., Tramontano E., 2018. Identification  
 515 of Myricetin as Ebolavirus VP35-dsRNA interaction inhibitor through a novel fluorescence-based  
 516 assay. Biochemistry, 57(44), 6367-6378. <https://doi.org/10.1021/acs.biochem.8b00892>.

517 de Oliveira Caleare A, Hensel A, Mello JCP, Pinha AB, Panizzon GP, Lechtenberg M, Petereit F,  
 518 Nakamura CV., 2017. Flavan-3-ols and proanthocyanidins from Limonium brasiliense inhibit the  
 519 adhesion of Porphyromonas gingivalis to epithelial host cells by interaction with gingipains.  
 520 Fitoterapia. 118, 87–93. <https://doi.org/10.1016/j.fitote.2017.03.002>.

521 Dettori C.A., Loi M.C., Brullo S., Fraga Arguimbau P., Tamburini E., Bacchetta G., 2016. The  
 522 genetic diversity and structure of the Ferula communis L. complex (Apiaceae) in the Tyrrhenian  
 523 area. Flora, 223, 138–146. <https://doi.org/10.1016/j.flora.2016.05.007>.

524 Dhifi W., Mnif W., Ouerhani B. & Ghrissi K., 2012. Chemical Composition and Antibacterial  
 525 Activity of Essential Oil from the Seeds of Pistacia terebinthus grown in Tunisia. J. Essent. Oil  
 526 Bear. Plants., 15:4, 582-58. <https://doi.org/10.1080/0972060X.2012.10644092>.

527 Dikpinar T.. Süzgeç-Selçuk S.. Çelik B.Ö.. Uruşak E.A.. 2018. Antimicrobial activity of rhizomes  
 528 of Ferulago trachycarpa Boiss. and bioguided isolation of active coumarin constituents. Ind. Crop.  
 529 Prod. 123, 762-767. <https://doi.org/10.1016/j.indcrop.2018.06.072>

530 Duru ME, Cakir A, Kordali S, Zengin H, Harmandar M, Izumi S, Hirata T., 2003. Chemical  
 531 composition and antifungal properties of essential oils of three Pistacia species. Fitoterapia. 74(1-  
 532 2), 170-176. [https://doi.org/10.1016/S0367-326X\(02\)00318-0](https://doi.org/10.1016/S0367-326X(02)00318-0).

533 Fois M, Fenu G, Cañadas EM, Bacchetta G., 2017. Disentangling the influence of environmental  
534 and anthropogenic factors on the distribution of endemic vascular plants in Sardinia. PLoS ONE  
535 12(8), e0182539. <https://doi.org/10.1371/journal.pone.0182539>.

536 Fokialakis N, Kalpoutzakis E, Tekwani BL, Khan SI, Kobaisy M, Skaltsounis AL, Duke SO., 2007.  
537 Evaluation of the antimalarial and antileishmanial activity of plants from the Greek island of Crete.  
538 J. Nat. Med. 61(1), 38–45. <https://doi.org/10.1007/s11418-006-0013-y>.

539 Fung T.T., Chiuve S.E, Willett W.C., Hankinson S.E., Hu F.B., Holmes M.D., 2013. Intake of  
540 specific fruits and vegetables in relation to risk of estrogen receptor-negative breast cancer among  
541 postmenopausal women. Breast Cancer Res. Treat. 138, 925-930. [https://doi.org/10.1007/s10549-](https://doi.org/10.1007/s10549-013-2484-3)  
542 013-2484-3.

543 Gadetskaya A V., Tarawneh AH, Zhusupova GE, Gemejiyeva NG, Cantrell CL, Cutler SJ, Ross  
544 SA. 2015. Sulfated phenolic compounds from *Limonium caspium*: Isolation, structural elucidation,  
545 and biological evaluation. Fitoterapia. 104,80–85. <https://doi.org/10.1016/j.fitote.2015.05.017>.

546 Gomes F., Martins N., Barros L., Rodrigues M.E., Oliveira M.B.P.P., Henriques M., Ferreira  
547 I.C.F.R., 2017. Plant phenolic extracts as an effective strategy to control Staphylococcus aureus, the  
548 dairy industry pathogen. Ind. Crop. Prod. 112, 515-520.  
549 <https://doi.org/10.1016/j.indcrop.2017.12.027>

550 Hosseinzadeh, H., & Nassiri-Asl, M., 2014. Review of the protective effects of rutin on the  
551 metabolic function as an important dietary flavonoid. J. Endocrinol. Invest. 37, 783-788.  
552 <https://doi.org/10.1007/s40618-014-0096-3>.

553 Ismail A., Lamia H., Mohsen H., Samia G., Bassem J., 2013. Chemical composition and antifungal  
554 activity of three Anacardiaceae species grown in Tunisia. Sci. Int. 1(5),148–154.  
555 <https://doi.org/10.5567/sciintl.2013.148.154>.

556 Jahangir M., Kim H.K., Choi Y.H., Verpoorte R., 2008. Metabolomic response of *Brassica rapa*  
 557 submitted to preharvest bacterial contamination. Food Chem. 107, 362-368.  
 558 <https://doi.org/10.1016/j.foodchem.2007.08.034>.

559 Kavak D.D., Altıok E., Bayraktar O., Ülkü S., 2010. *Pistacia terebinthus* extract: As a potential  
 560 antioxidant, antimicrobial and possible  $\beta$ -glucuronidase inhibitor. J. Mol. Catal. B-Enzym. 64(3-4),  
 561 167-171. <https://doi.org/10.1016/j.molcatb.2010.01.029>.

562 Kim, H.K., Choi, Y.H., & Verpoorte, R., 2010. NMR-based metabolomic analysis of plants. Nat.  
 563 Protoc. 5(3), 536. <https://doi.org/10.1038/nprot.2009.237>.

564 Kordali S, Cakir A, Zengin H, Duru ME., 2003. Antifungal activities of the leaves of three *Pistacia*  
 565 species grown in Turkey. Fitoterapia, 74(1-2),164-7. [https://doi.org/10.1016/S0367-](https://doi.org/10.1016/S0367-326X(02)00320-9)  
 566 [326X\(02\)00320-9](https://doi.org/10.1016/S0367-326X(02)00320-9).

567 Loi M.C., Frailis L., Maxia A., 2002. Medicinal plants commonly used in the Gesturi territory  
 568 (Central-Southern Sardinia). Atti Soc. Tosc. Sci. Nat. Mem. Ser. B. 109, 167–76.

569 Magiatis P, Pratsinis H, Kalpoutzakis E, Konstantinidou A, Davaris P, Skaltsounis AL., 2001.  
 570 Hydrolyzable tannins, the active constituents of three Greek *Cytinus* taxa against several tumor cell  
 571 lines. Biol. Pharm. Bull. 24(6), 707–709. <https://doi.org/10.1248/bpb.24.707>.

572 Mahady G, Lawal LO, Raut N, Wick SM., 2018. Natural products and traditional medicines for the  
 573 treatment of multidrug resistant bacteria. Medical Research Archives 6(1).  
 574 <https://doi.org/10.18103/mra.v6i1.1639>.

575 Mandrone M., Lorenzi B., Venditti A., Guarcini L., Bianco A., Sanna C., Ballero M., Poli F.,  
 576 Antognoni F., 2015. Antioxidant and anti-collagenase activity of *Hypericum hircinum* L. Ind. Crop.  
 577 Prod. 76, 402-408. <https://doi.org/10.1371/journal.pone.0195168>.

578 Mandrone M., Scognamiglio M., Fiorentino A., Sanna C., Cornioli L., Antognoni F., Bonvicini F.,  
579 Poli F., 2017 Phytochemical profile and  $\alpha$ -glucosidase inhibitory activity of Sardinian *Hypericum*  
580 *scruglii* and *Hypericum hircinum*. Fitoterapia, 120, 184-193.  
581 <https://doi.org/10.1016/j.fitote.2017.06.020>.

582 Mandrone, M., Coqueiro, A., Poli, F., Antognoni, F., Choi, Y.H., 2018. Identification of a  
583 collagenase-inhibiting flavonoid from *Alchemilla vulgaris* using NMR-based metabolomics. Planta  
584 Med., 84(12/13), 941-946. <https://doi.org/10.1055/a-0630-2079>.

585 Marengo A., Maxia A., Sanna C., Berteà C.M., Bicchi C., Ballero M., Cagliero C, Rubiolo P., 2017  
586 - Characterization of four wild edible *Carduus* species from the Mediterranean region via  
587 phytochemical and biomolecular analyses. Food Res. Int., 100. 822-831.  
588 <https://doi.org/10.1016/j.foodres.2017.07.071>.

589 Marengo A, Piras A, Falconieri D, Porcedda S, Caboni P, Cortis P, Foddìs C, Loi C, Gonçalves MJ,  
590 Salgueiro L, Maxia A., 2018. Chemical and biomolecular analyses to discriminate three taxa of  
591 *Pistacia* genus from Sardinia Island (Italy) and their antifungal activity. Nat. Prod. Res. 32(23):  
592 2766-2774. <https://doi.org/10.1080/14786419.2017.1378211>.

593 Marignani M., Bruschi D., Astiaso Garcia D., Frondoni R., Carli E., Pinna M.S., Cumo F.,  
594 Gugliermetti F., Saatkamp A., Doxa A., Queller E.M., Chaieb M., Bou Dagher-Kharrat M., El Zein  
595 R., El Jeitani S., Khater C., Mansour S., Al-Shami A., Harik G., Alameddine I., El-Fadel M., Blasi  
596 C., 2017. Identification and prioritization of areas with high environmental risk in Mediterranean  
597 coastal areas: A flexible approach. Sci. Total Environ. 590-591,566-578.  
598 <https://doi.org/10.1016/j.scitotenv.2017.02.221>.

599 Maxia A., Sanna C., Piras A., Porcedda S., Falconieri D., Gonçalves MJ., Cavaleiro C., Salgueiro  
600 L., 2015 - Chemical composition and biological activity of *Tanacetum audibertii* (Req.) DC.

601 (Asteraceae), an endemic species of Sardinia Island, Italy. Ind. Crop. Prod. 65, 472-476.  
 602 <https://doi.org/10.1016/j.indcrop.2014.10.039>.

603 May L., Klein E.Y., Rothman R. E., Laxminrayan R., 2014. Trends in Antibiotic Resistance in  
 604 Coagulase-Negative Staphylococci in the United States, 1999 to 2012. Antimicrob. Agents  
 605 Chemother. 58(3), 1404-1409. <https://doi.org/10.1128/AAC.01908-13>.

606 Medail F. & Quezel P., 1999. Biodiversity hotspots in the Mediterranean Basin: setting global  
 607 conservation priorities. Conserv. Biol., 13, 1510-1513.

608 Médail, F. & Quézel, P., 1997. Hot-spots analysis for conservation of plant biodiversity in the  
 609 Mediterranean Basin. Annals of the Missouri Botanical Garden. 84, 112-127.  
 610 <https://doi.org/10.2307/2399957>.

611 Medini F, Bourgou S, Lalancette K, Snoussi M, Mkadmini K, Coté I, Abdelly C, Legault J, Ksouri  
 612 R., 2015. Phytochemical analysis, antioxidant, anti-inflammatory, and anticancer activities of the  
 613 halophyte *Limonium densiflorum* extracts on human cell lines and murine macrophages. S. Afr. J.  
 614 Bot. 99, 158–164. <https://doi.org/10.1016/j.sajb.2015.04.007>.

615 Medini F, Fellah H, Ksouri R, Abdelly C., 2014. Total phenolic, flavonoid and tannin contents and  
 616 antioxidant and antimicrobial activities of organic extracts of shoots of the plant *Limonium*  
 617 *delicatulum*. J. Taibah Univ. Sci. 8,216–224. <https://doi.org/10.1016/j.jtusci.2014.01.003>.

618 Moellering R.C., 2012. MRSA: the first half century. J. Antimicrob. Chemother. 67, 4-11.  
 619 <https://doi.org/10.1093/jac/dkr437>.

620 Nordmann P., Naas T., Poirel L., 2011. Global spread of carbapenemae-producing  
 621 Enterobacteriaceae. Emerg. Infect. Dis. 17(10), 1791-1798.  
 622 <https://doi.org/10.3201/eid1710.110655>.

623 Orhan I.E., Sezer Senol F., Rifat Gulpinar A., Sekeroglu N., Kartal M., Sener B., 2012.  
 624 Neuroprotective potential of some terebinth coffee brands and the unprocessed fruits of *Pistacia*  
 625 *terebinthus* L. and their fatty and essential oil analyses. Food Chem. 130, 882–888.  
 626 <https://doi.org/10.1016/j.foodchem.2011.07.119>.

627 Ornano L., Venditti A., Donno Y., Sanna C., Ballero M., Bianco A., 2016 - Phytochemical analysis  
 628 of non-volatile fraction of *Artemisia caerulescens subsp. densiflora* (Viv.) (Asteraceae), An  
 629 endemic species of La Maddalena Archipelago (Sardinia-Italy). Nat. Prod. Res. 30, 920-925.  
 630 <https://doi.org/10.1080/14786419.2015.1079189>.

631 Ozcan, M., 2004. Characteristics of fruit and oil of terebinth (*Pistacia terebinthus* L.) growing wild  
 632 in Turkey. J. Sci. Food Agric. 84, 517–520. <https://doi.org/10.1002/jsfa.1632>.

633 Özcan, M. M., Tzakou, O., Couladis, M., 2009. Essential oil composition of the turpentine tree  
 634 (*Pistacia terebinthus* L.) fruits growing wild in Turkey. Food Chem. 114, 282–285.  
 635 <https://doi.org/10.1016/j.foodchem.2008.08.094>.

636 Piras A, Marzouki H, Maxia A, Marengo A, Porcedda S, Falconieri D, Gonçalves MJ, Cavaleiro C,  
 637 Salgueiro L., 2017. Chemical characterisation and biological activity of leaf essential oils obtained  
 638 from *Pistacia terebinthus* growing wild in Tunisia and Sardinia Island. Nat. Prod. Res. 31(22),  
 639 2684-2689. <https://doi.org/10.1080/14786419.2017.1289204>.

640 Polat R, Cakilcioglu U, Satil F., 2013. Traditional uses of medicinal plants in Solhan (Bingöl -  
 641 Turkey). J. Ethnopharmacol. 48(3), 951–63. <https://doi.org/10.1016/j.jep.2013.05.050>.

642 Pulaj B, Mustafa B, Nelson K, Quave CL, Hajdari A., 2016. Chemical composition and in vitro  
 643 antibacterial activity of *Pistacia terebinthus* essential oils derived from wild populations in Kosovo.  
 644 BMC Complement. Altern. Med. 16, 147–155. <https://doi.org/10.1186/s12906-016-1135-8>.

645 Rolo J., de Lencastre H., Miragaia M., 2012. Strategies of adaptation of *Staphylococcus epidermidis*  
646 to hospital and community: amplification and diversification of SCCmec. J. Antimicrob.  
647 Chemother. 67, 1333–1341. <https://doi.org/10.1093/jac/dks068>.

648 Sanna C, Rigano D, Corona A, Piano D, Formisano C, Farci D, Franzini G, Ballero M, Chianese G,  
649 Tramontano E, Taglialatela-Scafati O, Esposito F., 2018c - Dual HIV-1 reverse transcriptase and  
650 integrase inhibitors from *Limonium morisianum* Arrigoni, an endemic species of Sardinia (Italy).  
651 Nat. Prod. Res. 4, 1-6. <https://doi.org/10.1080/14786419.2018.1434649>.

652 Sanna C., Rigano D., Cortis P., Corona A., Ballero M., Parolin C., Del Vecchio C., Chianese G.,  
653 Saccon E., Formisano C., Tramontano E., Esposito F., 2018a - *Onopordum illyricum* L., a  
654 Mediterranean plant, as a source of anti HIV-1 compounds. Plant Biosyst.152(6), 1274-1281.  
655 <https://doi.org/10.1080/11263504.2018.1439118>.

656 Sanna C, Scognamiglio M, Fiorentino A, Corona A, Graziani V, Caredda A, Cortis P, Montisci M,  
657 Ceresola ER, Canducci F, Poli F., Tramontano E., Esposito F., 2018b. Prenylated phloroglucinols  
658 from *Hypericum scruglii*, an endemic species of Sardinia (Italy), as new dual HIV-1 inhibitors  
659 effective on HIV-1 replication. PLoS One. 13(3):e0195168.  
660 <https://doi.org/10.1371/journal.pone.0195168>.

661 Scavo A., Pandino G., Restuccia C., Parafati L., Cirvilleri G., Mauromicale G., 2019. Antimicrobial  
662 activity of cultivated cardoon (*Cynara cardunculus* L. var. *altilis* DC.) leaf extracts against bacterial  
663 species of agricultural and food interest. Ind. Crop. Prod. 129, 206-211.  
664 <https://doi.org/10.1016/j.indcrop.2018.12.005>

665 Schildknecht H., Herb R., Kunzelmann P., 1985. Die Chemie der Schmarotzerblumen, II.  
666 Isoterchebin: Struktur des gelben Ellagitannin-Farbstoffes aus *Cytinus hypocistis* (Rafflesiaceae).  
667 Liebigs Ann Chem, (7),1448–1456.



668 Schoina V., Terpou A., Gialleli A-I, Koutinas A, Kanellaki M, Bosnea L., 2015. Use of *Pistacia*  
 669 *terebinthus* resins immobilization support for *Lactobacillus casei* cells and application in selected  
 670 dairy products. J. Food Sci. Technol. 52, 5700–5708. <https://doi.org/10.1007/s13197-014-1627-9>.

671 Snene A., El Mokni R., Jmii H., Jlassi I., Jaïdane H., Falconieri D., Piras A., Dhaouadi H., Porcedda  
 672 S., Hammami S., 2017. In vitro antimicrobial, antioxidant and antiviral activities of the essential oil  
 673 and various extracts of wild (*Daucus virgatus* (Poir.) Maire) from Tunisia. Ind. Crop. Prod. 109,  
 674 109-115. <http://dx.doi.org/10.1016/j.indcrop.2017.08.015>

675 Toledo E., Salas-Salvadó J., Donat-Vargas C., Buil-Cosiales P., Estruch R., Ros E., Corella D., Fitó  
 676 M., Hu F.B., Arós F., Gómez-Gracia E., Romaguera D., Ortega- Calvo M., Serra-Majem L., Pintó  
 677 X., Schröder H., Basora J., Sorlí J.V., Bulló M., Serra-Mir M., Martínez-González M.A., 2015.  
 678 Mediterranean diet and invasive breast cancer risk among women at high cardiovascular risk in the  
 679 PREDIMED trial: a randomized clinical trial. JAMA Intern. Med. 175,1752-1760.  
 680 <https://doi.org/10.1001/jamainternmed.2015.4838>.

681 Topcu G, Ay M, Bilici A, Sarikuerkcue C, Oezturk M, Ulubelen A., 2007. A new flavone from  
 682 antioxidant extracts of *Pistacia terebinthus*. Food Chem. 103(3), 816–822.  
 683 <https://doi.org/10.1016/j.foodchem.2006.09.028>.

684 Ulukanli Z, Karaborklu S, Ozturk B, Çenet M, Balcilar M., 2014. Chemical composition,  
 685 antibacterial and insecticidal activities of the essential oil from the *Pistacia terebinthus* L. Spp.  
 686 Palaestina (Boiss.) (Anacardiaceae). J. Food Process. Preserv. 38(3), 815–822.  
 687 <https://doi.org/10.1111/jfpp.12035>.

688 Usai M, Pintore G, Chessa M, Tirillini B., 2006. Essential oil composition of different aerial parts  
 689 of *Pistacia terebinthus* L. growing wild in Sardinia. J. Essent. Oil Res. 18, 383–385.  
 690 <https://doi.org/10.1080/10412905.2006.9699121>.

691 Venditti A, Lattanzi C, Ornano L, Maggi F, Sanna C, Ballero M, Alvino A, Serafini M, Bianco A.,  
 692 2016 - A new glucosidic phthalide from *Helichrysum microphyllum subsp. tyrrhenicum* from La  
 693 Maddalena Island (Sardinia, Italy). Nat. Prod. Res. 30(7), 789-795.  
 694 <https://doi.org/10.1080/14786419.2015.1067619>.

695 Venditti A, Maggi F, Quassinti L, Bramucci M, Lupidi G, Ornano L, Ballero M, Sanna C, Bruno  
 696 M, Rosselli S, Bianco A., 2018. Bioactive Constituents of *Juniperus turbinata* Gussone from La  
 697 Maddalena Archipelago. Chem. Biodivers. 15, e1800148. <https://doi.org/10.1002/cbdv.201800148>.

698 Venditti A., Sanna C., Lorenzetti L.M., Ballero M., Bianco A., 2017 - New coumarinyl ethers in  
 699 *Daphne oleoides* Schreb. collected from Sardinia Island. Chem. Biodivers., 14 (6), e1700072.  
 700 <https://doi.org/10.1002/cbdv.201700072>.

701 Verpoorte, R., Choi, Y.H., & Kim, H.K., 2007. NMR-based metabolomics at work in  
 702 phytochemistry. Phytochem. Reviews, 6(1), 3-14. <https://doi.org/10.1007/s11101-006-9031-3>.

703 Wang M, Lamers RJ, Korthout HA, van Nesselrooij JH, Witkamp RF, van der Heijden R, Voshol  
 704 PJ, Havekes LM, Verpoorte R, van der Greef J., 2005. Metabolomics in the context of systems  
 705 biology: bridging traditional Chinese medicine and molecular pharmacology. Phytother. Res. 19,  
 706 173–182. DOI: 10.1002/ptr.1624

707 World Health Organization. 2014. Antimicrobial resistance: global report on surveillance.

708 Zucca P, Pintus M, Manzo G, Nieddu M, Steri D, Rinaldi AC., 2015. Antimicrobial, antioxidant  
 709 and anti-tyrosinase properties of extracts of the Mediterranean parasitic plant *Cytinus hypocistis*.  
 710 BMC Res. Notes. 8, 562. <https://doi.org/10.1186/s13104-015-1546-5>.